Zenas BioPharma, Inc. (ZBIO)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | - | 10,000 | - | |
| Research and development | 43,027 | 34,915 | 33,530 | |
| General and administrative | 12,136 | 12,415 | 7,454 | |
| Total operating expenses | 55,163 | 47,330 | 40,984 | |
| Loss from operations | -55,163 | -37,330 | -40,984 | |
| Other income, net | 2,960 | 3,552 | 2,378 | |
| Total other income (expense), net | 2,960 | 3,552 | 2,378 | |
| Loss before income taxes | -52,203 | -33,778 | - | |
| Income tax (provision) benefit | 20 | -205 | - | |
| Net loss to common stockholders | -52,223 | -33,573 | -38,606 | |
| Foreign currency translation adjustment | -265 | -65 | -50 | |
| Unrealized gain on investments | 30 | 12 | - | |
| Comprehensive loss | -52,458 | -33,626 | -38,656 | |
| Earnings per share, basic | -1.25 | -0.8 | -5.02 | |
| Earnings per share, diluted | -1.25 | -0.8 | -5.02 | |
| Weighted average number of shares outstanding, basic | 41,865,400 | 41,800,802 | 7,697,695 | |
| Weighted average number of shares outstanding, diluted | 41,865,400 | 41,800,802 | 7,697,695 | |